

In Silico Implementation of Evolutionary Paradigm in Therapy Design: Towards Anti-Cancer Therapy as Darwinian Process

B. Brutovsky

Department of Biophysics, Faculty of Science, Jesenna 5,
P. J. Safarik University, Jesenna 5, 04154 Kosice, Slovakia

D. Horvath

Technology and Innovation Park, Center of Interdisciplinary Biosciences,
P. J. Safarik University, Jesenna 5, 04154 Kosice, Slovakia

In here presented *in silico* study we suggest a way how to implement the evolutionary principles into anti-cancer therapy design. We hypothesize that instead of its ongoing supervised adaptation, the therapy may be constructed as a self-sustaining evolutionary process in a dynamic fitness landscape established implicitly by evolving cancer cells, microenvironment and the therapy itself. For these purposes, we replace a unified therapy with the ‘therapy species’, which is a population of heterogeneous elementary therapies, and propose a way how to turn the toxicity of the elementary therapy into its fitness in a way conforming to evolutionary causation. As a result, not only the therapies govern the evolution of different cell phenotypes, but the cells’ resistances govern the evolution of the therapies as well. We illustrate the approach by the minimalistic *ad hoc* evolutionary model. Its results indicate that the resistant cells could bias the evolution towards more toxic elementary therapies by inhibiting the less toxic ones. As the evolutionary causation of cancer drug resistance has been intensively studied for a few decades, we refer to cancer as a special case to illustrate purely theoretical analysis.

I. INTRODUCTION

Development of up-to-date anti-cancer therapies relies on the deep knowledge of specific biochemical machinery of cancer cells. However, despite improved understanding of the molecular details of cancer initiation and progression, many targeted therapies fail due to diversity of strategies of resistance deployed by cancer cells [1–4]. Presently, intratumor heterogeneity is viewed as the principal obstacle in the therapy design and many papers have reviewed its causes and consequences to therapeutic resistance during the last decades [5–12]. The mechanisms of resistance relate to altered activity of the specific enzyme systems, blocked apoptosis, developing transport mechanisms which provide multidrug resistance, etc. It was demonstrated that clonal that accumulation of the viable clonal genetic variants poses greater threat of progressing to cancer than the homogenizing clonal expansion [13]. Moreover, it is known for a long time that the epigenetic changes, such as DNA methylation, histone modifications, chromatin remodeling, and small RNA molecules, play the causative role in cancer initiation, progression [14–16] and resistance [17]. Considering the timescales during which mutations spread in a cancer cell population, the contribution of non-genetic instability in the intratumor heterogeneity of cancer cell populations is significant [18].

Another obstacle to efficient therapies consists in a static manner of the administration of most therapies which underestimates that many properties of cancer cells that contribute to the invasion, metastases and resistance likely arise as successful adap-

tive strategies to survive and proliferate within the temporally unstable micro-environmental conditions [19], induced, eventually, by the therapy itself. It was shown that the adaptive therapeutic intervention that reflects the temporal and spatial variability of the tumor microenvironment and cellular phenotype may provide substantially longer survival than the standard high dose density strategies [20].

Evolutionary Dynamics of Cancer. Since Nowell conceptualized carcinogenesis as the evolutionary process [21], evolutionary theory has been accepted as the appropriate conceptual base to get an insight into the *modus operandi* of cancer [21–23]. Evolutionary dynamics, in which the intratumor heterogeneity plays the crucial role, equips evolving populations of neoplastic cells with the adaptive power enabling them to cope with uncertain or time-varying micro-environmental conditions and it is considered as the main reason why the targeted therapy of cancer fails [24], and why the combination therapy, despite often improved therapeutic outcome, is still not the ultimate winner in the fight against cancer [25]. Nowadays, an effort to address the heterogeneity and variability of cancer cells in the therapy design is apparent [26, 27].

Therapeutic resilience of advanced cancers may be attributed not only to genetic diversity but to epigenetic plasticity as well [28]. A major difference between the epigenetic and genetic changes is that the epigenetic changes are reversible and, in principle, responsive to environmental influence. Variability in the phenotypic characteristics of isogenic cells confers to cellular tissues important properties, such as the ability of cancer cells to escape a targeted therapy by switch-

ing to an alternative phenotype [29, 30]. It motivates an effort to stimulate (or prevent) the specific phenotype switching purposefully as a therapeutic strategy [31, 32].

The interplay between the respective genomes, epigenomes, transcriptomes and proteomes constitutes a 'cell-state' [33]. Due to their tendency to be self-stabilizing, there are typically fewer distinct cell states in a tumor than it could be inferred from the degree of the genetic, epigenetic and transcriptional heterogeneity and, straightforwardly, genetically distinct cells may be susceptible to the treatment with the same drugs [34]. On the other hand, even genetically identical cells can, due to the epigenetic differences and influence of a microenvironment, exist in different cell states. Studying the cell-state dynamics of the isogenic population of human breast cancer cells revealed that the three phenotypic fractions (stem, basal and luminal) stay under the fixed genetic and environmental conditions in the equilibrium proportions and that individual cells transition from one state to another with constant interconversion rates [35]. Moreover, if the fractions were purposely deviated from the equilibrium, the equilibrium proportions were reestablished by interconversions between the cell states instead of differential growth of the respective phenotypic subpopulations. Therefore, Markov process was proposed as the appropriate mathematical model for the respective cell-state dynamics [35].

Presuming that the cells in different states differ in their growth properties, the cell-state composition of the cancer cell population becomes evolutionary important trait at the cancer-relevant timescales during which the cancer cells are exposed, in general, to changing environment (including the therapy). In this case, the population may benefit from maintaining the diversity of cell states, each advantageous within a different context [36, 37]. It was observed that in the case of variable selective pressure, the population of different organisms evolves the mechanisms to tune the phenotypic variability of the population to reflect the variability of the acting selective pressure [38]. In bacteria, the well known risk-diversification strategy evolved in populations when facing changing environment [39–41] is bet-hedging [42, 43]. This strategy increases the long-term survival and growth of an entire lineage instead of conferring an immediate fitness benefit to one individual [36]. Based on the formal similarity of evolving cancer cell population with bacteria, viruses or yeast, it has been recently proposed that the structure of intratumor heterogeneity is an evolutionary trait which evolves towards the maximum clonal fitness at the cancer-relevant timescale in changing (or uncertain) environment and that its structure corresponds to the bet-hedging strategy [44–47] which has been recently put into therapeutic context [48].

Distinguishing between the intratumor heterogeneity due to the differences in the DNA sequences and that resulting from the epigenetic modifications is instructive for the biological insight as well as for the 'physical' realization of an eventual therapy. Nevertheless, as the genetic and epigenetic changes differ primarily in their stabilities and characteristic timescales (both can be formulated probabilistically) and their contributions to the cell states may be intertwined, the two physical levels, genetic and epigenetic, need not be viewed separately [34]. For example, within the mathematical Markov model of the cell-state dynamics, the probabilities of transitions can be expressed by the elements of the transition matrix, not regarding whether genetic or epigenetic. Whether the epigenetic states are sufficiently stable [49] (i. e. whether probabilities of the respective transitions are low enough) to enable Darwinian evolution of isogenic cells underpinned by purely epigenetic states is an open question.

Evolutionarily Motivated Therapies. Cancer cells continuously evolve their ability to survive in time-varying microenvironment (as exemplified by developing the resistance against eventual therapeutic interventions). Consequently, to stay efficient, the therapy must be appropriately modified as well, which is typically arranged by the combination therapies and/or appropriate scheduling schemes which make attempts to solve this problem explicitly. In the strategy of benign cell boosters Maley and Forrest proposed firstly to increase the proliferation rate of the benign cells sensitive to a cytotoxin intentionally and then apply the toxin [50]. Similarly, Chen et al. designed strategy of an 'evolutionary trap' which selects from a karyotypically divergent population the subpopulation with predictably drugable karyotypic feature [51]. In the evolutionary double bind strategy to control cancer, Gatenby et al. exploit that the therapy resistance requires costly phenotypic adaptation that reduces the fitness of the respective cells [52]. It has been shown recently that the proliferation of malignant cells can be decreased by the administration of non (or minimally) cytotoxic ersatzdroges [53, 54] thereby the cell's resources are diverted from the proliferation and invasion towards the efflux pump activity, which, consequently, lowers the fraction of the cells with developed drug efflux mechanisms in the population [54]. During recent years, directed evolution of oncolytic viruses has been investigated in the virotherapy [55]. Instead of detailed knowledge of the molecular aspects of the interaction between the cancer cell and the virus, the approach exploits evolutionary principles such as diversified population of viral candidates which undergo purposefully designed selection steps to direct evolution towards an explicitly pre-defined goal. Usefulness of the approach was demonstrated by the adaptation of the RNA virus to the cells in which the tumor suppressor gene p53 had been inactivated [56].

Virotherapy is a targeted anticancer strategy in which genetically engineered strains of viruses replicate and lyse tumor cells [57]. Unfortunately, due to evolution of cancer cells the ultimate success of the treatment remains elusive. We hypothesize that even if one admits evolution of the virus, its fitness does not sufficiently reflect its ability to lyse cancer cells which, consequently, vanishes. In our work, the therapy is conceived as a self-sustaining evolutionary process in dynamic fitness landscape [58–61] with cytotoxicity of elementary therapies reflected in their respective fitness, which could prevent (or reduce) its decrease during eventual treatment.

II. MODEL

Evolutionary Causation of Toxicity. The ultimate goal of cancer research is to design the therapy which stays efficient against heterogeneous and continuously changing cancer cells with the minimum harm to healthy cells. To implement the evolutionary paradigm into the therapy design, we construct the therapy as a population of heterogeneous ‘elementary’ therapies (a ‘therapy species’) each of them allowed to interact exclusively with one of the available (therapy-free) cells (Fig. 1). Regarding the therapeutic context, the principal feature of the elementary therapy is its toxicity to cells. To undergo continuous, self-sustaining adaptation by the evolutionary process, toxicity of the elementary therapy must play the role of the therapy’s fitness, which means that it must conform to evolutionary causation.

Firstly toxicity of the elementary therapy must result from the real selection pressure, which means that the elementary therapy must be put into interaction with the cell. Secondly the evolutionary causation requires that during the treatment the fundamental evolutionary principles, phenotypic variation, differential fitness and heritability of fitness [62], apply. It follows that i) the elementary therapies differ in their respective toxicities, ii) the more toxic elementary therapy is, the more often it is applied, and, iii) repeated application of the same elementary therapy provides toxicity similar to that in its previous (i. e. ‘parent’) application, even if it is slightly changed (‘mutated’). While the points i) and iii) are straightforward and can be ensured by the appropriate heterogeneity of the elementary therapies, the point ii) is less intuitive and below we outline its minimalistic *in silico* implementation (Fig. 1).

In here proposed approach, each elementary therapy may create complex with one of the therapy-free cells. The elementary therapy can create the new complex with another therapy-free cell only after its current complex has decayed, playing the role of a catalyst. It follows that each cell-therapy complex is exposed, at the same time, to two counteracting selection pres-




FIG. 1: How toxicity turns into fitness. The red elementary therapy kills the cell sooner than the blue one therefore it can be applied more often. It means that the toxicity plays the role of reproduction fitness. If the therapy is not toxic, it stays within the complex and enables binding opportunity to free (i. e. more toxic) therapies.

ures. On the one hand, the fitness of the cell is proportional to the number of its copies, therefore longer lifetime of the complex (hence the resistance to therapy) is supported by the evolution of the target cell population. On the other hand, the complexes are under selection pressure due to the evolution of therapies; the sooner the elementary therapy kills the cells within its consecutive complexes, the higher is the number of its repetitions (hence, by definition, its reproduction fitness). Consequently, shorter lifetime of the complex (hence higher toxicity of the elementary therapies) is implicitly supported by the evolution of therapies. Despite the two evolutionary processes differ in their respective reproduction mechanisms, the former creating physical copies (cells), the latter repeating the therapies accordingly to their respective toxicities, the both processes satisfy one of the fundamental principles of evolution, the heritability of fitness, which does not require any particular mechanism of inheritance; only the correlation between the parent’s and offspring’s fitness is required [62]. To sum up, as in here proposed algorithm the number of iterations of an elementary therapy (hence its fitness) depends on the ability of the therapy to kill the cell, the toxicity of the elementary therapy can be identified with its fitness.

To illustrate the above conceptual approach (Fig. 1), we present in the following subsections its *in silico* implementation. We have devised two *ad hoc* models, the conceptual model of the target cell population and the model of a virtual elementary therapy and its interaction with the cell within the complex.

Feasibility of the respective algorithmic steps at biochemical and biological levels is not considered; short discussion about an eventual implementation of the approach is provided in the Conclusions.

Model of the Target Cell Population. During a few last decades many mathematical cancer models have been constructed, mostly classified as (i) continuum, formulated through differential equations, (ii) discrete lattice models, usually represented by cellular automata and, (iii) agent based with diverse levels of 'intelligence' assumed in the agents (for complete review of mathematical cancer models, see [63–68]). The respective types of models incorporate different levels of biological punctuality focusing on different scales, from microscopic to phenomenological. As in carcinogenesis many biological phenomena run concurrently, the multiscale models make an effort to bridge the gap between the phenomenology and microscopic theory [69, 70]. Evolutionary models of cancer do not typically focus on the microscales. The reason is that the phenotypes of cancer and normal cells can have many alternative genetic (and epigenetic) causes. Instead, evolution of cancer is driven by the environmental selection forces that interact with individual cellular strategies (or phenotypes) [19]. In this way, the evolutionary models investigate how selection pressure influence the life history characteristics, such as survival strategy, reproduction behavior, population heterogeneity, etc. [71–74].

The *ad hoc* choice of the genome-coded actions in our coarse-grained model of the cell reflects here adopted epitomization of target cells by cancer cells. As avoiding programmed cell death (apoptosis) is one of the hallmarks of cancer [75] no gene for it is assumed in the above set of actions; target cells die due to the lack of resources or to the therapy. On the other hand, the dormancy and phenotypic switching are included as they are often referred as possible alternative ways of drug resistance. As a result each target cell is defined by its state, $\phi \in \{0, 1\}$, enabling to quantify the impact of an elementary therapy on the cell, see below, and its 'genome' consisting of L genes $g_j \in \{R, M, S, D\}$, $j = 1 \dots L$, each representing specific cell-related action. The tuple $\mathcal{G} \equiv \langle L_R/L, L_M/L, L_S/L, L_D/L \rangle$, L_x being the number of gene x in the genome, is introduced to express proportions of the respective genes in the cell's genome. The actions associated with the respective genes correspond to: **(R)eplication:** the copy of the cell is created, unless the lack of resources prevents it, in which case the cell itself dies; if successful, the copy ('child') inherits the parent's genome and state and undergoes mutation, **(M)utation:** the gene is selected uniformly at random from the genome. If the selected gene is 'M', another gene selected uniformly at random is replaced by the gene picked with the same probability from $\{R, M, S, D\}$, **(S)witching:** the cell state is switched either from 1 to 0 or from 0 to 1, depending on the current state, and **(D)ormancy:**

no action is performed. Proportions of the respective gene in the genome of the cell determine its phenotype such as, for example, proliferative (abundance of 'R' genes), survival (abundance of 'D' genes), the cell state switching ('S' gene) and genetically unstable ('M' gene).

Model of the Elementary Therapy. In our model, a unified, biochemically reasoned therapy is replaced by the 'therapy species', which is evolving population of heterogeneous elementary therapies. Conceptual novelty of the approach (Fig. 1) consists in avoiding the necessity to specify explicitly the differences between cancer and normal cells, which is, due to intra-tumor heterogeneity, the principal obstacle in common treatments. Instead, it is required that the model of elementary therapy introduces variability in the cells' survival. It follows that to prevent 'premature convergence' (hence genetic drift) the population of elementary therapies must start as less (or non)toxic.

To facilitate the instructive *in silico* modeling, the elementary therapies are of the same mathematical structure based on two characteristics - the rate of change and the selectivity. These were chosen because they obviously influence the fate of the target cell as defined above, hence they guarantee the variability of the fitness within the population of elementary therapies. Nevertheless, in the eventual applications much less intuitive characteristics can be chosen, based on different pharmacological mechanisms of action.

The elementary therapy integrates all factors that effect the cell's fate into one time-dependent variable $\mathcal{E}(t)$, chosen to change continuously between 0 and 1 accordingly

$$\mathcal{E}(t) = \frac{1 \pm \sin(t/T)}{2}, \quad (1)$$

$2\pi T$ being the period of the respective therapy. The choice of the $+/-$ sign is arbitrary, nevertheless once chosen the sign persists during simulation.

To quantify selectivity of the therapy, \mathcal{S} , the threshold σ is defined as

$$\sigma = \frac{1}{1 + e^{\mathcal{S}(|\mathcal{E}(t) - \phi| - \mathcal{C})}}, \quad (2)$$

where $\mathcal{C} = 0.5$ postulates the symmetry of $\mathcal{E}(t)$ regarding the two possible cell states. In the next, we denote the therapy as the tuple $\mathcal{D} \equiv \langle T, \mathcal{S} \rangle$.

The threshold σ determines the fate of the cell, applying the rule

$$\text{action} = \begin{cases} \text{cell death, if } v_{rand} > \sigma, \\ \text{selected uniformly at random} \\ \text{from the genome, otherwise} \end{cases} \quad (3)$$

where $v_{rand} \in (0, 1)$ is uniformly distributed random number. Interaction of the therapy with the cell

(Eqs. 1 to 3) applies only if the action selected in Eq. (3) is the replication.

We emphasize that in the model the cell's resistance is not bound to a specific cell state ϕ but it is rather viewed as the ability of the cell(s) to survive under an instant therapy. For convenience, the cell in the state ϕ closer to $\mathcal{E}(t)$ is assigned with lower probability of death (Eqs. 2, 3). Regarding here followed therapeutic context it is viewed as *resistant*, while the cell in the complementary state (farther from the $\mathcal{E}(t)$, higher probability of death) is referred as *sensitive*. Taking into account the time variability of the therapy (Eq. 1) it follows that the cell can be resistant in one moment and sensitive in the other without switching its state.

Simulation Scheme. The simulation begins with the population of N cells characterized by their genomes \mathcal{G}_i and states ϕ_i , $i = 1 \dots N$, evolving simultaneously with the heterogeneous population of K therapies $\mathcal{D}_k \equiv \langle \mathcal{T}_k, \mathcal{S}_k \rangle$, $k = 1 \dots K$, (Eqs. 1, 2). Each genome \mathcal{G}_i , $i = 1 \dots N$, consists of L genes g_j , $j = 1 \dots L$, selected, at the beginning, uniformly at random from {R,M}. The states ϕ_i , $i = 1 \dots N$ are picked from {0,1} with the same probability. The therapy species is represented by K elementary therapies $\mathcal{D}_k = \langle \mathcal{T}_k, \mathcal{S}_k \rangle$, $k = 1 \dots K$, each of them with its own period $2\pi\mathcal{T}_k$ and selectivity \mathcal{S}_k , starting as

$$\mathcal{T}_k = 10^\xi \quad \text{and} \quad \mathcal{S}_k = 10^\eta, \quad k = 1 \dots K, \quad (4)$$

where $\xi \in (\xi_{min}, \xi_{max})$ and $\eta \in (\eta_{min}, \eta_{max})$ are uniformly distributed random numbers.

During simulation, the cells and therapies evolve accordingly to the model (Eqs. 1-3). The number of cells varies as implied by their interaction with elementary therapies and the population carrying capacity provided by the system resources. At replication, the newly born cell inherits its state and genome from its parent, and the both genomes undergo the above described mutation procedure. In addition, the offspring cell creates exclusive lifetime complex with one of the free elementary therapies. In contrast to the variable size of the population of cells, the size of the therapy species is kept constant; elementary therapies neither replicate, nor die; they only mutate every time when they form the complex with the cell; the mutated therapies are obtained as

$$\mathcal{T}_k^{new} = \mathcal{T}_k^{old} \times 10^{\delta_1} \quad \text{and} \quad \mathcal{S}_k^{new} = \mathcal{S}_k^{old} \times 10^{\delta_2}, \quad (5)$$

where $\delta_1, \delta_2 \in (0, 0.1)$ are uniformly distributed random numbers. Subsequently, the values of parameters within required intervals are guaranteed by imposing the limits as

$$\tilde{X} = \begin{cases} X \times 10^{\gamma_{max} - \gamma_{min}}, & \text{for } X < 10^{\gamma_{min}}, \\ X \times 10^{\gamma_{min} - \gamma_{max}}, & \text{for } X > 10^{\gamma_{max}}, \\ X, & \text{otherwise} \end{cases} \quad (6)$$

where X stands for \mathcal{T}_k^{new} or \mathcal{S}_k^{new} and γ for the respective ξ or η in Eq. 4.

During its lifetime, the cell repeatedly chooses uniformly at random the gene from its genome and performs the respective actions. If the action is replication, the interaction of the cell and its respective elementary therapy is recalculated (Eqs. 1- 3). If the cell survives, it replicates. When the cell dies, either due to the interaction with the therapy or due to the lack of resources at the moment of replication, its respective complex decays and the relinquished elementary therapy becomes capable to create complex with another newly born cell, playing the role of a catalyst.

III. RESULTS

Here, the cell state dynamics is represented by the dependence of the ratio N^1/N on the variable $\mathcal{E}(t)$; N^1 and N are numbers of the cells in the state $\phi = 1$ and the target cell population size, respectively. Due to fundamentally different physical implementation of the model system, with biological time scales and carrying capacity substituted by the CPU and memory limits (see Appendix), numerical values of \mathcal{T} and \mathcal{S} in the figures below lack biological meaning and are used only to outline a few typical behaviors of the model. Despite that, some results, such as the dependence of the cell state dynamics on the relations between some of the parameters could have universal meaning. In the subsections C and D, $\mathcal{E}(t)$ (Eq. 1) was calculated for each cell-therapy complex separately, with time t corresponding to the cell's age expressed as the CPU time consumed by the cell's thread (running in parallel with other threads, see Appendix) instead of simulation (i. e. 'physical') time, providing $\mathcal{E}(0) = 0.5$ at the cell's birth. Consequently, the ranges of \mathcal{T} of elementary therapies chosen in the Results sections A and B differ in orders of magnitude from those in sections C and D.

To get deeper insight into below *in silico* investigation of the evolutionary dynamics of the cells and elementary therapies, we have firstly studied a few cases of the cell state dynamics where at least one population, cells or therapies, was kept homogeneous (i. e. isogenic or unified, respectively) and did not evolve. Though most of presented features are rather obvious by intuition, for the readers' convenience we point out the most dominant of them.

A. Isogenic target cell population under unified therapy

Firstly dependences of the cell state dynamics on the three model characteristics, selectivity and period of the unified therapy and the cell's switching rate (L_S/L in \mathcal{G}_{iso}), were investigated. Fig. 2 shows convergence of the $(N^1/N, \mathcal{E})$ trajectories for the respective combinations of the above three model characteristics. The three nonevolving isogenic target cell populations which differ each other in the cells' switching rates, i) no switching, $\mathcal{G}_{iso} = \langle 0.5, 0, 0, 0.5 \rangle$, ii) low switch-

ing, $\mathcal{G}_{iso} = \langle 0.5, 0, 0.02, 0.48 \rangle$, and iii) high switching, $\mathcal{G}_{iso} = \langle 0.5, 0, 0.5, 0 \rangle$, were exposed one by one to 8 different unified therapies $\mathcal{D}_{uni} = \langle T, S \rangle$, combining a few different periods $2\pi T$ ($T = 400, 100, 40, 10$ ms) and selectivities ($S = 1, 30$). We note that to satisfy the genome's constraint $(L_R + L_M + L_S + L_D)/L = 1$, the change in the switching rate L_S/L is compensated by

the respective change of the probability of dormancy, L_D/L . Nevertheless, taking into account minor role of the dormancy within our illustrative model, we omit analysis of this step. Isogenic populations consisted of a few thousands non-evolving cells in the states ϕ_i , $i = 1 \dots N$, each picked from $\{0, 1\}$ with the same probability.




FIG. 2: Examples of the cell state dynamics of non-evolving populations of isogenic cells which differ by the probability of the cell state switching - no switching, low ($L_S/L = 0.02$) and high ($L_S/L = 0.5$) switching probability; for each of the populations two kinds of therapies are applied - low and highly selective, respectively, quantified by the values of the parameter $S = 1$ and 30 , respectively. Moreover, for all the cases four unified therapies differing in their respective periods are applied, as quantified by the values of the parameter $T = 400, 100, 40$ and 10 ms in (1). In each plot two series corresponding to the plus (red) or minus (black) sign in Eq. (1) are depicted.

In the case without switching, $\mathcal{G}_{iso} = \langle 0.5, 0, 0, 0.5 \rangle$, the population becomes extinct if the period $2\pi T$ is too long ($T = 400$ ms in Figs. 2A, 2B, 3A, and 3B) for the survival of the sensitive cells. The probability of extinction increases with higher selectivity of the therapy (Figs. 3A and 3B). In the case of low selectivity, $S = 1.0$, and the shortest investigated period given by $T = 10$ ms, the ability to switch the cell state does not affect the cell state dynamics significantly (Fig. 2A to C). However, high selectivity, $S = 30.0$, can homogenize the cell states in the population even during very short period without switching (Fig. 2B, $T = 10$ ms). Between the two limiting periods, corresponding to $T = 400$ ms and $T = 10$ ms, respectively, the population does not become extinct and converges to one of the two cell states. When the phenotype switching is allowed, the typical hysteretic behavior of the cell state dynamics emerges for the selectivity $S = 30$ (Figs. 2D and 2E, the period given by $T = 400$ ms) with the width of hysteretic loop decreasing with the switching probability. It is obvious that

the similar cell state dynamics can be produced alternatively (Figs. 2C, $T = 400$ ms and 2F, $T = 100$ ms), which indicates dependence of the cell state dynamics on a scaling form constructed between selectivity, period and the rate of switching.

We note that the relation between hysteresis and phenotype switching in evolutionary systems has often been observed and studied [76]. It was shown in bacteria that some antibiotics can induce long-lasting changes in their physiology, termed cellular hysteresis, that influence bactericidal activity of other antibiotics and can be exploited to optimize antibiotic therapy [77]. However, keeping in mind *ad hoc* choice of the model aimed in particular to provide formal fitness landscapes for here investigated purposes, we leave deeper analysis of the specific hysteretic behavior (or the memory effects caused by the therapy) of the cell state dynamics and, eventually, the scaling properties to future research.




FIG. 3: Dependence of the target cell population size on the period and selectivity of the therapy and the rate of switching of isogenic cells. Obviously, under higher selectivity the system follows dynamics of $\mathcal{E}(t)$ unless too short period (here, corresponding to the case $T = 10$ ms).

B. Evolving target cell population under unified therapy

In this subsection, the target cell population (for its initialization see simulation scheme in Section II) evolves under a few unified therapies $\mathcal{D}_{uni} = \langle T, S \rangle$ which differ by their periods $2\pi T$ and selectivities S . In the case of short periods, here corresponding to $\mathcal{D}_{uni} = \langle 1, 1 \rangle$ and $\langle 1, 30 \rangle$, the switching probabilities L_S/L in the population converged to 0.02 (Figs. 4A,B), which is the lowest possible nonzero value within the model resolution. In the case of long periods, corresponding to the unified therapies $\mathcal{D}_{uni} = \langle 100, 1 \rangle$ and $\langle 100, 30 \rangle$, no switching has evolved (Figs. 4E to F). When the therapies with intermediate periods, $\mathcal{D}_{uni} = \langle 10, 1 \rangle$ and $\langle 10, 30 \rangle$, are applied, higher se-

lectivity makes population more state homogeneous and, at the same time, decreases switching probabilities (Figs. 4C, D).

In the previous subsection we demonstrated sensitivity of the cell state dynamics on the period $2\pi T$ and the selectivity S of the therapy as implemented in the model (Eqs. 1-6) as well as on the switching probability. In this subsection the interplay between the period $2\pi T$ and selectivity S of the therapy and the evolution of switching probability was shown in more depth and the consequences of evolving it (or not) for the cell state dynamics.

The results presented in this and the previous subsections are very general and reflect simplicity of the

above *ad hoc* models. To obtain biologically more relevant outcome, biologically realistic timescales for the replication, phenotypic switching, apoptosis, carrying capacity, etc, would be needed. Nevertheless, regarding the context of our work we require the capability of the model to generate sufficient variability of the cell state dynamics, which has been demonstrated.




FIG. 4: Evolution of the switching rate under 6 different unified therapies $\mathcal{D}_{uni} = \langle T, S \rangle$, where the short period therapy uses $T = 1$ s, intermediate $T = 10$ s, and the long period therapy $T = 100$ s. The sizes of the target cell population and the switching rates in the genome after the population becomes isogenic are rescaled to emphasize dependences of the respective series on the variable $\mathcal{E}(t)$. Population size counts the both cell states, 0 and 1; however, at the $\mathcal{E}(t)$ extrema one of the states (alternately) dominates.

C. Isogenic target cell population under evolving therapy

Here, the relation between toxicities of the elementary therapies and their fitness was investigated. Toxicity of the elementary therapy is represented by the average lifetime of the cells which have applied it, and the fitness of the therapy corresponds to the number of its iterations, i. e. its abundance within the space of all possible elementary therapies spanned by the intervals $(\xi_{min}, \xi_{max}) \times (\eta_{min}, \eta_{max})$ (Eq. 4).

In simulations, the therapy species consisting of $K = 32768$ elementary therapies $\mathcal{D}_k = \langle \mathcal{T}_k, \mathcal{S}_k \rangle$, $k = 1 \dots K$, evolves in interaction with non-evolving isogenic populations (4 populations with different switching probabilities were one by one tested, $\mathcal{G}_{iso} =$

$\langle 0.5, 0, 0, 0.5 \rangle$, $\langle 0.5, 0, 0.02, 0.48 \rangle$, $\langle 0.5, 0, 0.2, 0.3 \rangle$ and $\langle 0.5, 0, 0.5, 0 \rangle$). At the beginning, the cell states ϕ_i , $i = 1 \dots N$, were picked from $\{0, 1\}$ with the same probability and the elementary therapies' parameters \mathcal{T}_k and \mathcal{S}_k , $k = 1 \dots K$, determining the periods and selectivities of the respective elementary therapies (Eq. 2), were generated accordingly to Eq. 4 for $\xi \in (2, 9)$ and $\eta \in (0, 3)$. The new ('mutated') elementary therapies were obtained from Eq. 5 imposing the boundary conditions (Eq. 6) with $\delta_1, \delta_2 \in (0, 0.1)$.

The simulation results show that increase of the switching probabilities in isogenic target cell populations makes the distributions of average lifetimes, as well as the density of the therapy space, flatter (Fig. 5). The average lifetimes of the cells under evolving therapies presented in Figs. 5 and 6 were $\approx 52 \mu\text{s}$ for $\mathcal{G}_{iso} = \langle 0.5, 0, 0, 0.5 \rangle$, $\approx 52 \mu\text{s}$ for $\mathcal{G}_{iso} = \langle 0.5, 0, 0.02, 0.48 \rangle$, $\approx 46 \mu\text{s}$ for $\mathcal{G}_{iso} = \langle 0.5, 0, 0.2, 0.3 \rangle$ and $\approx 39 \mu\text{s}$ for $\mathcal{G}_{iso} = \langle 0.5, 0, 0.5, 0 \rangle$.




FIG. 5: The average lifetimes of the cells (upper surfaces) which apply the same elementary therapy versus number of its applications (expressed as the density of the discretized $(\xi_{min}, \xi_{max}) \times (\eta_{min}, \eta_{max})$ therapy space, bottom surfaces, a. u. standing for arbitrary units). The plots A to D show the results for 4 isogenic target populations \mathcal{G}_{iso} which differ in switching probabilities. The surfaces corresponding to the density of therapy space are rescaled for the demonstration purposes; the heat maps of the respective densities of the therapy space (bottom surfaces) are shown more precisely in Fig. 6A to D.

The main result of this subsection (Figs. 5, 6) is that less toxic elementary therapies (conferring to cells longer average lifetimes) become less abundant in the therapy species. Moreover, the flatness of the distribution and the average lifetime of the cells depend on the switching probability encoded in the genomes.




FIG. 6: The heat maps show more precisely the density of the therapy space for the corresponding populations in Fig. 5. Colors of the heat maps are scaled to sharpen positions of the extrema in the surfaces.

D. Evolving target cell population under evolving therapy

Here, the population of therapies evolves simultaneously with the population of cells. Dependence of the average lifetimes of the cells on applied therapies, specified by the parameters \mathcal{T} and \mathcal{S} , was investigated. As the density of the therapy space is recorded after the population of target cells has converged to isogenic ($\mathcal{G}_{iso} = \langle 0.6, 0, 0, 0.4 \rangle$) the differences in the cells' lifetimes are attributed exclusively to the applied therapies. Evolved switching probability was 0, which is consistent with the findings in the previous subsection that, in this specific case, the absence of switching increases the average lifetime of cells. Fig. 7 shows that the therapies conferring, on average, longer lifetimes to the respective cells are underrepresented in the therapy species and vice versa.

The explanation of the anticorrelation is straightforward. Each cell, at its birth, creates the exclusive complex with one of the available elementary therapies (which 'mutates'). Even neither in the case of long living cell (dormant cell or the cell resistant to its respective therapy) is the therapy replaced. It might seem (therapeutically) contraproductive, as it contradicts to an intuitive expectation that the resistant cells should be the primary target of therapies, as resisting the cell death is one of the hallmarks of cancer cells [75]. As it was discussed above, here the fitness of the therapy corresponds to the number of its iterations (instead of the number of its physical copies). Straightforwardly, the therapeutic effort is to arrange that more fit (toxic) elementary therapies are applied

more often, and vice versa, if the therapy is not efficient, it should be repeated only rarely (to preserve the exploration capability of the algorithm). The anticorrelation in Fig. 7 implies that the less efficient therapy is, the less often it is used, which is the desired result. The message is that if it is not possible to determine *a priori* which therapy is the best (and to apply it), one should eliminate less fit therapies (to increase the abundance of the more toxic ones).




FIG. 7: Comparison of the average lifetimes of the cells which applied the same elementary therapy (upper surface in plot A) with the density of the space of elementary therapies (bottom surface in A, a.u. standing for the arbitrary units). As the density of the therapy space is recorded after the population has converged to isogenic ($\mathcal{G}_{iso} = \langle 0.6, 0, 0, 0.4 \rangle$), the average lifetimes depend only on the respective elementary therapies. The corresponding heat maps B, C underline the correlation of the area of the above-average lifetimes (bright yellow area in plots A, B) with sparsely populated areas in the therapy space (deep violet area in plots A, C).

IV. DISCUSSION

In here presented scenario, the resistant cells implicitly serve as inhibitors for non (or less) efficient therapies. By this way, the resistant cells direct the evolution of the therapy species to more efficient therapies. Here, it is required that the elementary therapy can create complex with the next therapy-free cell only after its current cell's death. By this, toxicity of the therapy is connected with its fitness in the evolution conforming way. However, this requirement disregards that many cancers evolve multidrug resistance by up-regulating membrane efflux pump that exports drugs,

thereby ensuring the cell's survival. As in this case the therapy is pumped out before it can fully exhibit its particular properties (primarily its toxicity), evolution of elementary therapies becomes questionable as one of the crucial evolutionary principle, the differential fitness [62], is significantly suppressed. On the other hand, the efflux pump comes with the energetic cost [78] which makes the cells with the efflux pump less fit than those without it when the therapy is absent (or nontoxic [53, 54]).

In here presented conceptualization, the therapies are heterogeneous, each of them interacting with the cells with heterogeneous properties, including the differences in their sensitivity to different therapies. If the cell pumps out the therapies not regarding their respective toxicities, it wastes resources and becomes less fit. Therefore, we speculate that in reality the cells would evolve mechanism(s) enabling them to extrude therapies reflecting the level of their respective toxicity. If true, more toxic therapies prevail in population, just as in here investigated case when the death of the cell was required to re-apply its therapy by the next cell. It would mean that the toxicity plays, from the evolutionary viewpoint, the role of the fitness of the therapy no matter whether it shortens the cell's lifetime, or redirects the cell's resources from replication and invasion to building efflux mechanism(s).

In here presented algorithm, each newly born cell creates the complex with the therapy which is, in general, different from the therapy of its parent. It follows, that even if the offspring has inherited resistance against the therapy of its parent, it might still be sensitive to its own, in addition mutated, therapy, which obviously decreases its (as well as its parent's) fitness. This effect might be more pronounced in the case of cells with unlimited replicative potential, which is one of the cancer hallmarks [79]. This adds more biological flavor to the model, as most chemotherapeutic drugs are designed to effectively target fast-dividing cells.

V. CONCLUSIONS

In the paper, a unified therapy is substituted by the therapy species, the evolving constant size population of heterogeneous elementary therapies, each of them with the fitness resulting *a posteriori* from its interaction with the cells and vice versa. In this way, not only the therapies govern the evolution of different phenotypes, but the variable resistances of the cells govern the evolution of the therapies as well. From the viewpoint of evolving elementary therapies, evolving population of target cells plays the role of dynamical environment. As the therapies themselves mutate, less dense areas of the therapy space are repeatedly repopulated by diffusion, retaining exploratory power of algorithm. Our *in silico* investigation indicates that the

algorithm can identify the most efficient therapies by inhibiting those which are less efficient (as evidenced by their lower ability to kill the host cell). Not being tailored to some specific molecular mechanisms responsible for the respective cancerous features, the approach could, in principle, cope with intratumor heterogeneity and stay efficient during adaptation of cancer cells to changed therapy.

Despite conceptual simplicity of the above approach we foresee a number of technical difficulties in its eventual therapeutic implementation. The ultimate question, i. e. which species will be the winner of the evolutionary 'arms race' - cancer or therapy - stays therefore unanswered in our paper. Each evolutionary process samples its respective search space with some specific efficiency. While the efficiency of the sampling by cancer cells population results from their biochemistry, in the case of the therapy species the efficiency of sampling would derive from its eventual therapeutic realization. The questions follow: What agent could be used as the replication-deficient therapy species? Must it be organic at all? How to mutate the therapies? How to deliver the elementary therapy into the cell, and, subsequently, to avoid the efflux pump, etc. Some of the above issues are omnipresent in cancer research and are intensively studied. Important insights could be gained from the virotherapy where the evolutionary principles are used to direct evolution towards the explicitly pre-defined goal, and the virus-based gene-therapy which uses the replication-deficient viruses as vectors.

Recently, the framework for classifying tumors according to their evolvability was presented [74], based on the diversity of neoplastic cells and its changes over time (constituting the Evo-index) on the one hand, and the environmental hazard and availability of resources (Eco-index) on the other hand. The authors of the above paper envision that in the future, the classification could indicate how the tumor of the respective type of evolvability would change with different therapy, helping so clinicians to choose the interventions regarding evolvability of the respective neoplasms. Our work enables to study the interplay between related characteristics, such as the phenotype switching and mutability, which reflect diversity of the target cell population and its changes over time and could eventually play the role of the Evo-index. Similarly, the environmental hazard is in our work represented by the selectivity of the therapy. The resources are implicitly (and, in principle, unavoidably) included in the model. Variability of the selection pressure is mediated by the different periods of elementary therapies. Owing to this we believe that here presented approach could contribute to better understanding of the relation between evolvability of cancer and dynamics of environment (hence the therapy).

In his iconoclastic paper [80], Leonard Adleman proposed that computationally hard problems, such as

therein presented NP-complete directed Hamiltonian path problem, can be efficiently solved with the algorithmic steps realized by the standard tools of molecular biology. We hope that here speculated possible benefits of yet conceptual approach could, perhaps, motivate cancer researchers to test its feasibility in a therapeutically relevant way.

ACKNOWLEDGMENTS

This work was supported by the Scientific Grant Agency of the Ministry of Education of Slovak Republic (VEGA) under the grants No. 1/0250/18 and 1/0156/18.

-
- [1] Gottesman, M. M. 2002 Mechanisms of cancer drug resistance *Annu. Rev. Med.* **53**, 615–627.
 - [2] Bedard, P. L., Hansen, A. R., Ratain, M. J. & Siu, L. L. 2013 Tumour heterogeneity in the clinic *Nature* **501**, 355–364.
 - [3] Gallaher, J. A., Enriquez-Navas, P. M., Luddy, K. A., Gatenby, R. A. & Anderson, A. R. A. 2018 Spatial heterogeneity and evolutionary dynamics modulate time to recurrence in continuous and adaptive cancer therapies *Cancer Res.* **78**, 2127–2139.
 - [4] Gatenby, R. & Brown, J. 2018 The evolution and ecology of resistance in cancer therapy *Cold Spring Harb. Perspect. Med.* **8**, a033415.
 - [5] Turner, N. C. & Reis-Filho, J. S. 2012 Genetic heterogeneity and cancer drug resistance *Lancet* **13**, e178–85.
 - [6] Saunders, N. A., Simpson, F., Thompson, E. W., Hill, M. M., Endo-Munoz, L., Leggatt, G., Minchin, R. F. & Guminski, A. 2012 Role of intratumoural heterogeneity in cancer drug resistance: molecular and clinical perspectives *EMBO Mol. Med.* **4**, 675–684.
 - [7] Marusyk, A. & Polyak, K. 2010 Tumor heterogeneity: Causes and consequences *Biochim. Biophys. Acta* **1805**, 105–117.
 - [8] Marusyk, A., Almendro, V. & Polyak, K. 2012 Intra-tumour heterogeneity: a looking glass for cancer? *Nat. Rev. Cancer* **12**, 323–334.
 - [9] Marusyk, A. & Polyak, K. 2013 Cancer cell phenotypes, in fifty shades of grey *Science* **339**, 528–529.
 - [10] Meacham, C. E. & Morrison, S. J. 2013 Tumour heterogeneity and cancer cell plasticity *Nature* **501**, 328–337.
 - [11] Burrell, R. A., McGranahan, N., Bartek, J. & Swanton, C. 2013 The causes and consequences of genetic heterogeneity in cancer evolution *Nature* **501**, 338–345.
 - [12] Fisher, R., Pusztai, L. & Swanton, C. 2013 Cancer heterogeneity: implications for targeted therapeutics *Br. J. Cancer* **108**, 479–485.
 - [13] Maley, C. C., Galipeau, P. C., Finley, J. C., Wongsurawat, V. J., Li, X., Sanchez, C. A., Paulson, T. G., Blount, P. L., Risques, R. A., Rabinovitch, P. S. *et al.* 2006 Genetic clonal diversity predicts progression to esophageal adenocarcinoma *Nat. Genet.* **38**, 468–473.
 - [14] Laird, P. W. 2005 Cancer epigenetics *Hum. Mol. Gen.* **14**, R65–R76.
 - [15] Bjornsson, H. T., Fallin, M. D. & Feinberg, A. P. 2004 An integrated epigenetic and genetic approach to common human disease *Trends Genet.* **20**, 350–358.
 - [16] Easwaran, H., Tsai, H. C. & Baylin, S. B. 2014 Cancer epigenetics: Tumor heterogeneity, plasticity of stem-like states, and drug resistance *Mol. Cell* **54**, 716–727.
 - [17] Hölzel, M., Bovier, A. & Tüting, T. 2013 Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance? *Nat. Rev. Cancer* **13**, 365–376.
 - [18] Huang, S. 2013 Genetic and non-genetic instability in tumor progression: link between the fitness landscape and the epigenetic landscape of cancer cells *Cancer Metastasis Rev.* **32**, 423–448.
 - [19] Gillies, R. J., Brown, J. S., Anderson, A. R. A. & Gatenby, R. A. 2018 Eco-evolutionary causes and consequences of temporal changes in intratumoural blood flow *Nat. Rev. Cancer* **18**, 576–585.
 - [20] Gatenby, R. A., Silva, A. S., Gillies, R. J. & Frieden, B. R. 2009 Adaptive therapy *Cancer Res.* **69**, 4894–4903.
 - [21] Nowell, P. C. 1976 The clonal evolution of tumor cell populations *Science* **194**, 23–28.
 - [22] Merlo, L. M. F., Pepper, J. W., Reid, B. J. & Maley, C. C. 2006 Cancer as an evolutionary and ecological process *Nat. Rev. Cancer* **6**, 924–935.
 - [23] Greaves, M. 2007 Darwinian medicine: a case for cancer *Nat. Rev. Cancer* **7**, 213–221.
 - [24] Gillies, R. J., Verduzo, D. & Gatenby, R. A. 2012 Evolutionary dynamics of carcinogenesis and why targeted therapy does not work *Nat. Rev. Cancer* **12**, 487–493.
 - [25] Bozic, I., Reiter, J. G., Allen, B., Antal, T., Chatterjee, K., Shah, P., Moon, Y. S., Yaqubie, A., Kelly, N., Le, D. T. *et al.* 2013 Evolutionary dynamics of cancer in response to targeted combination therapy *eLIFE* **2**, e00747.
 - [26] Amirouchene-Angelozzi, N., Swanton, C. & Bardelli, A. 2017 Tumor evolution as a therapeutic target *Cancer Discov.* **7**, 805–817.
 - [27] Zhang, J., Cunningham, J. J., Brown, J. S. & Gatenby, R. A. 2017 Integrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancer *Nat. Commun.* **8**, art. 1816.
 - [28] Greaves, M. 2015 Evolutionary Determinants of Cancer *Cancer Discov.* **5**, 806–820.
 - [29] Kemper, K., de Goeje, P. L., Peeper, D. S. & van Amerongen, R. 2014 Phenotype switching: Tumor cell plasticity as a resistance mechanism and target for therapy *Cancer Res.* **74**, 5937–5941.
 - [30] Emmons, M. F., Faião-Flores, F. & Smalley, K. S. M. 2016 The role of phenotypic plasticity in the escape of cancer cells from targeted therapy *Biochem. Pharmacol.* **122**, 1–9.
 - [31] Saez-Ayala, M., Montenegro, M. F., del Campo, L. S., Fernandez-Perez, M. P., Chazarra, S., Freter, R., Middleton, M.,

- Pinero-Madrona, A., Cabezas-Herrera, J., Goding, C. R. *et al.* 2013 Directed phenotype switching as an effective antime-
lanoma strategy *Cancer Cell* **24**, 105–119.
- [32] Montenegro, M. F., del Campo, L. S., Fernandez-Perez, M. P., Saez-Ayala, M., Cabezas-Herrera, J. & Rodriguez-Lopez, J. N. 2015 Targeting the epigenetic machinery of cancer cells *Oncogene* **34**, 135–143.
- [33] Clevers, H., Rafelski, S., Elowitz, M., Klein, A., Shendure, J., Trapnell, C., Lein, E., Lundberg, E., Uhlen, M., Martinez-Arias, A. *et al.* 2017 What is your conceptual definition of "cell type" in the context of a mature organism? *Cell Systems* **4**, 255–259.
- [34] Alizadeh, A. A., Aranda, V., Bardelli, A., Blanpain, C., Bock, C., Borowski, C., Caldas, C., Califano, A., Doherty, M., Elsner, M. *et al.* 2015 Toward understanding and exploiting tumor heterogeneity *Nat. Med.* **21**, 846–853.
- [35] Gupta, P. B., Fillmore, C. M., Jiang, G., Shapira, S. D., Tao, K., Kuperwasser, C. & Lander, E. S. 2011 Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells *Cell* **146**, 633–644.
- [36] Carja, O. & Plotkin, J. B. 2017 The evolutionary advantage of heritable phenotypic heterogeneity *Sci. Rep.* **7**, 5090.
- [37] Dueck, H., Eberwine, J. & Kim, J. 2016 Variation is function: Are single cell differences functionally important? *BioEssays* **38**, 172–180.
- [38] Rando, O. J. & Verstrepen, K. J. 2007 Timescales of genetic and epigenetic inheritance *Cell* **128**, 655–668.
- [39] Crean, A. J. & Marshall, D. J. 2009 Coping with environmental uncertainty: dynamic bet hedging as a maternal effect *Phil. Trans. R. Soc. B* **364**, 1087–1096.
- [40] Forbes, S. 2009 Portfolio theory and how parent birds manage investment risk *OIKOS* **118**, 1561–1569.
- [41] Beaumont, H. J. E., Gallie, J., Kost, C., Ferguson, G. C. & Rainey, P. B. 2009 Experimental evolution of bet hedging *Nature* **462**, 90–94.
- [42] de Jong, I., Haccou, P. & Kuipers, O. P. 2011 Bet hedging or not? A guide to proper classification of microbial survival strategies *BioEssays* **33**, 215–223.
- [43] Donaldson-Matasci, M. C., Lachmann, M. & Bergstrom, C. T. 2008 Phenotypic diversity as an adaptation to environmental uncertainty *Evol. Ecol. Res.* **10**, 493–515.
- [44] Chisholm, R. H., Lorenzi, T. & Clairambault, J. 2016 Cell population heterogeneity and evolution towards drug resistance in cancer: Biological and mathematical assessment, theoretical treatment optimisation *Biochim. Biophys. Acta* **1860**, 2627–2645.
- [45] Nichol, D., Robertson-Tessi, M., Jeavons, P. & Anderson, A. R. A. 2016 Stochasticity in the genotype-phenotype map: Implications for the robustness and persistence of bet-hedging *Genetics* **204**, 1523–1539.
- [46] Gravenmier, C. A., Siddique, M. & Gatenby, R. A. 2018 Adaptation to stochastic temporal variations in intratumoral blood flow: The Warburg effect as a bet hedging strategy *Bull. Math. Biol.* **80**, 954–970.
- [47] Thomas, F., Ujvari, B., Gideon, C., Tasiemski, A., Ewald, P. W. & Roche, B. 2017 Toward an ultimate explanation of intratumor heterogeneity in B. Ujvari, B. Roche & F. Thomas, editors, *Ecology and evolution of cancer* Elsevier.
- [48] Mathis, R. A., Sokol, E. S. & Gupta, P. B. 2017 Cancer cells exhibit clonal diversity in phenotypic plasticity *Open Biol.* **7**, 160283.
- [49] Herman, J. J., Spencer, H. G., Donohue, K. & Sultan, S. E. 2014 How stable 'should' epigenetic modifications be? Insights from adaptive plasticity and bet-hedging *Evolution* **68**, 632–643.
- [50] Maley, C. C., Reid, B. J. & Forrest, S. 2004 Cancer prevention strategies that address the evolutionary dynamics of neoplastic cells: Simulating benign cell boosters and selection for chemosensitivity *Cancer Epidemiol. Biomark. Prev.* **13**, 1375–1384.
- [51] Chen, G., Mulla, W. A., Kucharavy, A., Tsai, H. J., Rubinstein, B., Conkright, J., McCroskey, S., Bradford, W. D., Weems, L., Haug, J. S. *et al.* 2015 Targeting the adaptability of heterogeneous aneuploids *Cell* **160**, 771–784.
- [52] Gatenby, R. A., Brown, J. & Vincent, T. 2009 Lessons from applied ecology: Cancer control using an evolutionary double bind *Cancer Res.* **69**, 7499–7502.
- [53] Kam, Y., Das, T., Tian, H., Foroutan, P., Ruiz, E., Martinez, G., Minton, S., Gillies, R. J. & Gatenby, R. A. 2015 Sweat but no gain: Inhibiting proliferation of multidrug resistant cancer cells with "ersatzdroges" *Int. J. Cancer* **136**, E188–E196.
- [54] Enriquez-Navas, P. M., Wojtkowiak, J. W. & Gatenby, R. A. 2015 Application of evolutionary principles to cancer therapy *Cancer Res.* **75**, 4675–4680.
- [55] Sanjuan, R. & Grdzlishvili, V. Z. 2015 Evolution of oncolytic viruses *Curr. Opin. Virol.* **13**, 1–5.
- [56] Garijo, R., Hernandez-Alonso, P., Rivas, C., Diallo, J. S. & Sanjuan, R. 2014 Experimental evolution of an oncolytic vesicular stomatitis virus with increased selectivity for p53-deficient cells *PLoS ONE* **9**, e102365.
- [57] Jenner, A. L., Kim, P. S. & Frascoli, F. 2019 Oncolytic virotherapy for tumours following a gompertz growth law *J. Theor. Biol.* **480**, 129–140 doi:<https://doi.org/10.1016/j.jtbi.2019.08.002>.
- [58] Holland, J. H. 1975 *Adaptation in natural and artificial systems* University of Michigan.
- [59] Levins, R. 1968 *Evolution in Changing Environments: Some Theoretical Explorations* Princeton University Press.
- [60] Branke, J. 2002 *Evolutionary Optimization in Dynamic Environments* Kluwer Academic Publishers.
- [61] Morrison, R. W. 2004 *Designing Evolutionary Algorithms for Dynamic Environments* Springer.
- [62] Lewontin, R. C. 1970 The units of selection *Annu. Rev. Ecol. Syst.* **1**, 1–18.
- [63] Anderson, A. R. A. & Chaplain, M. A. J. 1998 Continuous and discrete mathematical models of tumor-induced angiogenesis *Bull. Math. Biol.* **60**, 857–900.
- [64] Preziosi, L., editor 2003 *Cancer Modelling and Simulation* Chapman&Hall/CRC Press.
- [65] Bellomo, N., Li, N. K. & Maini, P. K. 2008 On the foundations of cancer modelling: Selected topics, speculations, and perspectives *Math. Mod. Meth. Appl. S.* **18**, 593–646.
- [66] Lowengrub, J. S., Frieboes, H. B., Jin, F., Chuang, Y.-L., Li, X., Macklin, P., Wise, S. M. & Cristini, V. 2010 Nonlinear modelling of cancer: bridging the gap between cells and tumours *Nonlinearity* **23**, R1–R91.

- [67] Wodarz, D. & Komarova, N. L. 2014 *Dynamics of Cancer: Mathematical Foundations of Oncology* World Scientific, London.
- [68] Altrock, P. M., Liu, L. L. & Michor, F. 2015 The mathematics of cancer: integrating quantitative models *Nat. Rev. Cancer* **15**, 730–745.
- [69] Deisboeck, T. S. & Stomatakos, G. S., editors 2011 *Multiscale Cancer Modeling* Chapman&Hall/CRC Press.
- [70] Cristini, V. & Lowengrub, J. 2010 *Multiscale Modeling of Cancer: An Integrated Experimental and Mathematical Modeling Approach* Cambridge University Press, Cambridge.
- [71] Aktipis, C. A., Boddy, A. M., Gatenby, R. A., Brown, J. S. & Maley, C. C. 2013 Life history trade-offs in cancer evolution *Nat. Rev. Cancer* **13**, 883–892.
- [72] Korolev, K. S., Xavier, J. B. & Gore, J. 2014 Turning ecology and evolution against cancer *Nat. Rev. Cancer* **14**, 371–380.
- [73] Abbott, R. G. & Forrest, S. 2006 Simulating hallmarks of cancer *Artif. Life* **12**, 617–634.
- [74] Maley, C. C., Aktipis, A., Graham, T. A., Sottoriva, A., Boddy, A. M., Janiszewska, M., Silva, A. S., Gerlinger, M., Yuan, Y., Pienta, K. J. *et al.* 2017 Classifying the evolutionary and ecological features of neoplasms *Nat. Rev. Cancer* **17**, 605–619.
- [75] Hanahan, D. & Weinberg, R. A. 2011 Hallmarks of cancer: The next generation *Cell* **144**, 646–674.
- [76] Friedman, G., McCarthy, S. & Rachinskii, D. 2014 Hysteresis can grant fitness in stochastically varying environment *PLoS ONE* **7**, e103241.
- [77] Roemhild, R., Gokhale, C. S., Dirksen, P., Blake, C., Rosenstiel, P., Traulsen, A., Andersson, D. I. & Schulenburg, H. 2018 Cellular hysteresis as a principle to maximize the efficacy of antibiotic therapy *Proc. Natl. Acad. Sci. USA* **115**, 9767–9772.
- [78] Silva, A. S., Kam, Y., Khin, Z. P., end R. J. Gillies, S. E. M. & Gatenby, R. A. 2012 Evolutionary approaches to prolong progression-free survival in breast cancer *Cancer Res.* **72**, 6362–6370.
- [79] Hanahan, D. & Weinberg, R. A. 2000 The hallmarks of cancer *Cell* **100**, 57–70.
- [80] Adleman, L. M. 1994 Molecular computation of solutions to combinatorial problems *Science* **266**, 1021–1023.
- [81] Kerrisk, M. 2010 *The Linux Programming Interface: A Linux and UNIX System Programming Handbook* No Starch Press, San Francisco, CA, USA 1st edition.

APPENDIX

The program encoding the above model conforms to the POSIX Threads execution scheme with the round-robin time sharing as implemented in the Linux programming interface API [81], enabling to execute the respective cells concurrently as separate threads. More important than an eventual CPU gain, accruing from the program parallelism, is the benefit from delegating some of the model’s parameters to the respective system CPU and memory resources. For example, the size of the cell population derives, apart from the cells’ genomes themselves, from the maximum number of concurrently running threads allowed by the system (representing ‘carrying capacity’ of the population), duration of the thread creation (being the counterpart of the cell replication), size of the thread stack, etc. Owing to the implicit substitution of some model parameters by the system parameters, the implementation of the model is more robust, simpler

and enable to concentrate on particular biologically relevant aspects, such as demonstrated by the above results. Obviously, the hardware constraints can be viewed as the counterpart of the constraints implied by biochemistry which are always present in biological experiments.

Our specific hardware restrictions, such as the maximum allowed concurrently running threads in the system, duration of the thread creation (hundreds of nanoseconds) and cancellation processes, etc, enabled us to simulate populations close to maximum size $N \approx 10000$, Fig. 3. In summary, between 10^7 and 10^8 ($\approx 10^4$ per second) cell-therapy complexes could be tested in a 1-hour simulation. The number of elementary therapies in the therapy species during simulations was kept constant ($K = 32768$), reflecting the particular hardware implementation.